

CI Bio-Revolution Index ETF (formerly CI Bio-Revolution ETF)

SUMMARY OF INVESTMENT PORTFOLIO as at September 30, 2023

Category	% of Net Assets	Category	% of Net Assets	Top 25 Holdings	% of Net Assets
Country allocation		Sector allocation		Twist Bioscience Corp.	3.5
U.S.A.	76.6	Health Care	99.0	Vertex Pharmaceuticals Inc.	3.3
Switzerland	7.1	Cash & Cash Equivalents	0.7	BioNTech SE, ADR	3.1
China	4.5	Foreign Currency Forward Contract(s)	0.4	Novartis AG, Registered	3.0
Germany	3.1	Other Net Assets (Liabilities)	(0.1)	Thermo Fisher Scientific Inc.	3.0
Netherlands	1.7			AbbVie Inc.	2.8
South Korea	1.7			Gilead Sciences Inc.	2.8
Denmark	1.7			Biogen Inc.	2.7
U.K.	1.2			Bristol-Myers Squibb Co.	2.7
Ireland	1.1			Eli Lilly and Co.	2.6
Cash & Cash Equivalents	0.7			Seagen Inc.	2.6
Foreign Currency Forward Contract(s)	0.4			Moderna Inc.	2.5
Jersey	0.3			Exact Sciences Corp.	2.4
Other Net Assets (Liabilities)	(0.1)			Genscript Biotech Corp.	2.4
				Pfizer Inc.	2.4
				CRISPR Therapeutics AG	2.3
				Catalent Inc.	2.3
				Editas Medicine Inc.	2.3
				Intellia Therapeutics Inc.	2.3
				Agilent Technologies Inc.	2.2
				Innovent Biologics Inc.	2.1
				Legend Biotech Corp., ADR	2.1
				Sanofi SA	2.1
				Beam Therapeutics Inc.	2.0
				10X Genomics Inc., Class A	1.9
				Total Net Assets (in \$000's)	\$4,926

The summary of investment portfolio may change due to ongoing portfolio transactions of the Fund and updates are available on a quarterly basis.

The prospectus and other information about the fund are available on the internet at www.ci.com.

